Pfizer Surpasses Sales Projections, Thanks to Resurgence of Aging Blockbusters Pharmaceutical giant Pfizer has exceeded sales expectations, driven by the unexpected resurgence of its older, flagship medications. According to a recent report, the company's blockbusters, which were initially expected to decline in sales, have instead seen a significant uptick in revenue. This shift in fortunes has not only boosted Pfizer's bottom line but also raised hopes for the pharmaceutical industry, which has been grappling with the challenges of patent expirations and declining sales of older medications. As Pfizer's stock price continues to rise, investors are taking notice of the company's ability to breathe new life into its aging portfolio of drugs.
Pfizer tops sales estimates as older blockbusters outperform Crain's New York Business
